SBI Healthcare Opportunities Fund Direct Growth
NAV as on 17-04-2025
₹ 471.98
▲0.9%
1D
Inception Returns
18.2%
/yr
Historical NAV & Returns
Absolute
▲
▼
3733 people have invested ₹ 3.5Cr in SBI Healthcare Opportunities Fund Direct Growth in the last three months
About SBI Healthcare Opportunities Fund Direct Growth
SBI Healthcare Opportunities Fund Direct Growth is an equity fund. This fund was started on 1 January, 2013. The fund is managed by Tanmaya Desai. The fund could potentially beat inflation in the long-run.
Key Parameters
- SBI Healthcare Opportunities Fund Direct Growth has ₹3611 Cr worth of assets under management (AUM) as on Mar 2025 and is more than category average.
- The fund has an expense ratio 0.9.
Returns
SBI Healthcare Opportunities Fund Direct Growth has given a CAGR return of 18.24% since inception. Over the last 1, 3 and 5 years the fund has given a CAGR return of 21.64%, 23.93% and 26.46% respectively.
Holdings
SBI Healthcare Opportunities Fund Direct Growth has allocated its funds majorly in Cash Equivalent, Health, Basic Materials. Its top holdings are Sun Pharmaceuticals Industries Ltd, Max Healthcare Institute Ltd Ordinary Shares, Divi's Laboratories Ltd, Cipla Ltd, Lupin Ltd
Taxation
As it is a sector - healthcare mutual fund the taxation is as follows:For short term (less than a year) capital gains will be taxed at 20%For long term (more than 1 year) capital gains will be taxed at 12.5% without indexation benefitDividends will always be taxed at slab rate. Long term gains upto Rs 1 lakh are exempt capital gains tax.
Investment objective of SBI Healthcare Opportunities Fund Direct Growth
To provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space.
Minimum Investment and lockin period
Minimum investment for lump sum payment is INR 5000.00 and for SIP is INR 500.00. SBI Healthcare Opportunities Fund Direct Growth has no lock in period.
SBI Healthcare Opportunities Fund Direct Growth Overview
| Expense ratio | 0.9% |
Benchmark | BSE Healthcare TR INR |
| AUM | ₹3611 Cr |
| Inception Date | 1 January, 2013 |
| Min Lumpsum/SIP | ₹5000/₹500 |
Exit Load | 0.5% |
| Lock In | No Lock-in |
TurnOver | 43.14% |
| STCG | Selling mutual fund before 1 year, returns taxed at 20%. |
| LTCG | After 1 year, 12.5% tax on returns over ₹1.25 lakh/year. |
| Risk |   Very High Risk |
INDmoney Rank for SBI Healthcare Opportunities Fund Direct Growth
Powered by IND quant engine
IND ranking is not available for this fund.
5Y returns in the top 25% of the category
3Y returns in the top 25% of the category
Beats FD returns for both 3Y & 5Y duration
No bad points found for this fund.
Trailing Returns
as on (17-Apr-25)
Fund Distribution
as on (31-Mar-25)
Small cap
36.9%
Mid cap
28.7%
Large cap
26.9%
Sector Allocation
Health
93.2%
Basic Materials
6.8%
All changes are between Jan'25 and Mar'25
- This fund’s returns stands at 7.45% whereas the fund’s underlying benchmark Nifty 500 returns stands at 7.25% as on Mar'25
- This fund outperformed Nifty 500 by 0.20% in Mar'25
- AUM of the fund stands at 3.6K Cr as of Mar'25
- AUM increased by 297.6 Cr between Mar'25 and Feb'25
Top Stocks bought last month
Concord Biotech Ltd's allocation increased from 0.9% to 1.29%
Laurus Labs Ltd's allocation increased from 2.71% to 3.06%
Aurobindo Pharma Ltd's allocation increased from 2.3% to 2.57%
Top Stocks sold last month
Sun Pharmaceuticals Industries Ltd's allocation decreased from 13.47 % to 13.45 %
Divi's Laboratories Ltd's allocation decreased from 6.2 % to 6 %
Cipla Ltd's allocation decreased from 5.1 % to 4.79 %
Mid Cap allocation has gone up from 28.6% to 28.7%
Large Cap allocation has gone down from 27.4% to 26.9%
Small Cap allocation has gone up from 36.2% to 36.9%
Cash allocation has gone up from 2.6% to 3%
Debt allocation has gone down from 0.1% to 0%
Top 3 Sectors in March were Health, Basic Materials & Government
Mar'25
Health
93%
Basic Materials
7%
Feb'25
Health
93%
Basic Materials
7%
Government
3%
Holdings | Weight% | 1M Change | |
|---|---|---|---|
 Sun Pharmaceuticals Industries Ltd | 13.45% | 0% | |
 Max Healthcare Institute Ltd Ordinary Shares | 6.68% | 0% | |
 Divi's Laboratories Ltd | 6% | 0% | |
 Cipla Ltd | 4.79% | 0% | |
 Lupin Ltd | 4.72% | 0% |
See all
Funds | 1Y Returns | 3Y Returns | 5Y Returns | Since Inception |
|---|---|---|---|---|
SBI Healthcare Opportunities Fund Direct Growth | 21.64% | 23.93% | 26.46% | 18.24% |
 UTI Healthcare Fund-Growth Option- Direct | 22.13% | 20.25% | 23.63% | 16.18% |
 ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth | 21.02% | 23.46% | 26.57% | 22.41% |
 LIC MF Healthcare Fund Direct Growth | 19.78% | 16.88% | 19.64% | 20.06% |
See all
Top Growth Drivers | 1M Return |
|---|---|
 Krishna Institute of Medical Sciences Ltd | 12.8% |
 Max Healthcare Institute Ltd | 6.6% |
 Sun Pharmaceutical Industries Ltd | 0.2% |
Loading...
We are taking more time than usual
Tanmaya Desai
Fund Manager of SBI Healthcare Opportunities Fund Direct Growth, since 1 June 2011
Top funds managed
Fund House
SBI Funds Management Ltd
Total Schemes
Total AUM
₹7.37L Cr
as on 31-Mar-2025
Address
9th Floor, Crescenzo,,C-38 & 39, G Block, Bandra Kurla Complex,,Bandra (East), Mumbai
Phone
91-22-66142900
Website
partnerforlife@sbimf.com
Mutual Fund Insights
In the last 1 year, HDFC Pharma and Healthcare Fund Direct Growth has given 29.31% return, outperforming this fund by 7.67%.
Over the last 1 month, this fund has experienced a 9.0% growth in AUM moving from 3.31K Cr to 3.61K Cr.
In the last 5 years, ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth has given 26.57% return, outperforming this fund by 0.11% per annum.
Over the last 15 months, this fund has decreased expense ratio by 10.9% moving from 1.01 to 0.90.
This fund has one of the lowest expense ratio in the category (sector - healthcare). Its expense ratio is 0.9% which is lower than the category average expense ratio of 1.41%.
In the last 3 years, this fund has outperformed all funds in its category.
SBI Healthcare Opportunities Fund Direct Growth Highlights
Very High Risk
Investors understand that their principal will be at Very High Risk
About the fund
This fund has delivered an average annual returns of 18.24% since inception which is more than its category average return of 17.07%
Fund Allocations
This fund has an allocation of 96.96% in Equity, 0% in Debt and 3.04% in Cash related instruments
AUM size ₹3611 Cr
This fund has AUM of ₹3611 Cr which is more than its category average of ₹ 1821 Cr
Expense Ratio 0.9%
This fund has an expense ratio of 0.9% which is less than its category average expense ratio of 1.44%
Most Popular Comparisons
- Compare
SBI Healthcare Opportunities FundVs
Nippon India Pharma Fund Direct Growth
- Compare
- SBI Healthcare Opportunities FundVs
ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth
- Compare
- SBI Healthcare Opportunities FundVs
DSP Healthcare Fund Direct Growth
- Compare
- SBI Healthcare Opportunities FundVs
Mirae Asset Healthcare Fund Direct Growth
- Compare
- SBI Healthcare Opportunities FundVs
UTI Healthcare Fund Direct Growth
More funds from SBI
5Y CAGR
▲ 31.28
5Y CAGR
▲ 31.68
5Y CAGR
▲ 29.53
5Y CAGR
▲ 35.50
5Y CAGR
▲ 24.73
Frequently Asked Questions for SBI Healthcare Opportunities Fund Direct Growth
The current NAV of SBI Healthcare Opportunities Fund Direct Growth is ₹471.98 as on 17-Apr-2025.
Existing (Absolute + CAGR) as on 17-Apr-2025.
SBI Healthcare Opportunities Fund Direct Growth | Absolute Returns | CAGR Returns |
1 Month Returns | 4.06% | 4.06% |
6 Month Returns | -0.93% | -0.93% |
1 Year Returns | 21.64% | 21.64% |
3 Years Returns | 90.35% | 23.93% |
With INDmoney, the process of investing is very simple and involves zero commission.
- Click Buy on the fund name.
- Input the amount you are looking to invest.
- Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
- Select your bank account and proceed with Payment.
0.9% as on March 2025
₹3611 Cr as on March 2025
Sun Pharmaceuticals Industries Ltd(13.45%), Max Healthcare Institute Ltd Ordinary Shares(6.68%), Divi's Laboratories Ltd(6%), Cipla Ltd(4.79%), Lupin Ltd(4.72%) as on March 2025
The alpha ratio for the SBI Healthcare Opportunities Fund Direct Growth for various period is as follows:
Fund Name | Alpha 1 Year | Alpha 3 Years | Alpha 5 Years |
SBI Healthcare Opportunities Fund Direct Growth | 3.56 | 5.03 | 4.31 |
As on March 2025
The alpha for SBI Healthcare Opportunities Fund Direct Growth is calculated against BSE Healthcare TR INR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the SBI Healthcare Opportunities Fund Direct Growth for various period is as follows:
Fund Name | Beta 1 Year | Beta 3 Years | Beta 5 Years |
SBI Healthcare Opportunities Fund Direct Growth | 0.82 | 0.85 | 0.86 |
As on March 2025
The Beta for SBI Healthcare Opportunities Fund Direct Growth is calculated with BSE Healthcare TR INR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the SBI Healthcare Opportunities Fund Direct Growth for various period is as follows:
Fund Name | Sharpe Ratio 1 Year | Sharpe Ratio 3 Years | Sharpe Ratio 5 Years |
SBI Healthcare Opportunities Fund Direct Growth | 0.83 | 1.12 | 1.32 |
As on March 2025
The sharpe ratio for SBI Healthcare Opportunities Fund Direct Growth is calculated with BSE Healthcare TR INR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the SBI Healthcare Opportunities Fund Direct Growth for various period is as follows:
Fund Name | Standard Deviation 1 Year | Standard Deviation 3 Years | Standard Deviation 5 Years |
SBI Healthcare Opportunities Fund Direct Growth | 16.66 | 14.93 | 17.57 |
As on March 2025
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
Sortino ratio is 1.96 as on March 2025. Sortino ratio tells the downside risk-adjusted-returns of the mutual fund.
Information ratio is 1 as on March 2025. It tells the consistency of the fund in generating superior risk-adjusted performance
Tanmaya Desai is the fund manager of SBI Healthcare Opportunities Fund Direct Growth
The Exit load of SBI Healthcare Opportunities Fund Direct Growth is 0.5%